Merck

YTD

ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other.

CEO

Robert M. Davis

CEORobert M. Davis

Employees

75,000

Employees75,000

Headquarters

Rahway, New Jersey

HeadquartersRahway, New Jersey

Founded

1891

Founded1891

Employees

75,000

Employees75,000

MRK Key Statistics

Market cap

217.29B

Market cap217.29B

Price-Earnings ratio

13.27

Price-Earnings ratio13.27

Dividend yield

3.72%

Dividend yield3.72%

Average volume

10.01M

Average volume10.01M

High today

$87.84

High today$87.84

Low today

$86.40

Low today$86.40

Open price

$86.91

Open price$86.91

Volume

6.17M

Volume6.17M

52 Week high

$120.30

52 Week high$120.30

52 Week low

$73.31

52 Week low$73.31

MRK News

Simply Wall St 9h

Should Breakthrough FDA Status for Novel Lung Cancer Drug Prompt Action From Merck Investors?

Earlier this week, Daiichi Sankyo and Merck announced that ifinatamab deruxtecan received Breakthrough Therapy Designation from the U.S. FDA for adults with ext...

TipRanks 9h

Merck & Co.’s Strategic Positioning and Market Potential Justify Buy Rating Despite Challenges

Analyst Asad Haider of Goldman Sachs maintained a Buy rating on Merck & Company, retaining the price target of $94.00. Elevate Your Investing Strategy: Take adv...

Seeking Alpha 2d

Merck shares snapped six-session winning streak

Merck (NYSE:MRK) shares snapped six straight sessions of gains, as the stock was down 0.1% at $84.85 on Wednesday. The pharmaceutical giant added nearly 6% in...

Analyst ratings

56%

of 25 ratings

Buy

56%

Hold

44%

Sell

More MRK News

Simply Wall St 3d

Merck Antibody Drug Ifinatamab Deruxtecan Gains Breakthrough Therapy Designation

Recent advancements in Merck's (MRK) product portfolio, including the FDA's Breakthrough Therapy Designation for ifinatamab deruxtecan and several approvals of...

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.